OR WAIT null SECS
© 2022 MJH Life Sciences and Pharmaceutical Commerce. All rights reserved.
© 2022 MJH Life Sciences™ and Pharmaceutical Commerce. All rights reserved.
January 29, 2015
Roughly 40% are for rare diseases; PD-1 oncolytics capture industry attention
Mapi Group casts itself as a leading 'health research and commercialization' player
'Stay tuned' for interactions directly with pharma companies, says CEO Jeff Tangney
So long WAG, hello to WBA as pharma manufacturers look at a consolidating buyer landscape
Pharmacists' ranking, continuing a two-year decline, is now neck-and-neck with doctors
Express Scripts touts a 'fundamental change' in drug pricing; others would call it negotiating a discount
Acquisition builds on Dohmen's rare-disease business
Poltraf acquisition adds to a network of 14 facilities serving Eastern and Western Europe
Will formularies become a consumer's concern for healthcare provision?
January 28, 2015
The broad changes taking place in the pharma supply chain this year are a relevant focus for the annual conference and exhibition
FDA enforcement delay to May 1 isn't slowing down project work
Company hires Kevin O'Donnell, cold chain expert, to build out its Biologistex shipping service
Cloud computing opens a new array of benefits--and challenges--to data-sharing
Persistent drug shortages are mostly attributable to manufacturing quality problems, but the economics of low-margin generic manufacturing challenge the industry
January 27, 2015
When state and federal governments are involved, prices and reimbursements have both regulatory and financial consequences
Outsourced field sales is becoming only part of what CSOs are offering their pharma clients
Publicis Touchpoint Solutions does a deal with Cegedim Relationship Management
Internal compliance reviews are not enough; life sciences companies need to assess their third-party business partners
Defining 'market access'
Compliance issues around sampling will be featured at upcoming conference